The present disclosure relates to a spiro compound and application thereof. The spiro compound has a structure as shown in a formula (1). The material provided in the present disclosure has advantages such as high optical and electrical stability, low sublimation temperature, low drive current, low lateral mobility of carriers, high luminous efficiency, and long service life of a device, and can be used in an organic electroluminescent device. In particular, the compound has the possibility of being applied in the AMOLED industry as a hole injection or transport material.

The present disclosure relates to a spiro compound and application thereof. The spiro compound has a structure as shown in a formula (1). The material provided in the present disclosure has advantages such as high optical and electrical stability, low sublimation temperature, low drive current, low lateral mobility of carriers, high luminous efficiency, and long service life of a device, and can be used in an organic electroluminescent device. In particular, the compound has the possibility of being applied in the AMOLED industry as a hole injection or transport material.

The disclosure provides a naphthylurea compound having a formula I. In the formula, m and n represent a number of CH.sub.2, and are an integer from 1 to 10; k and z represent a number of CH.sub.2, and are an integer from 0 to 6; and p represents a number of CH.sub.2, and is 1, 2 or 3; and X is O or S.

The disclosure provides a naphthylurea compound having a formula I. In the formula, m and n represent a number of CH.sub.2, and are an integer from 1 to 10; k and z represent a number of CH.sub.2, and are an integer from 0 to 6; and p represents a number of CH.sub.2, and is 1, 2 or 3; and X is O or S.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

The present invention provides a compound represented by formula (i), a liquid crystal composition using the compound, and a liquid crystal display device using the liquid crystal composition. The compound represented by formula (i) has a partial structure K.sup.i1 represented by any of general formulas (K-1) to (K-17) and further has ring B having at least two P-Sp- groups. Therefore, when used for a liquid crystal composition, the compound adsorbs to substrates sandwiching the liquid crystal composition (liquid crystal layer) and allows liquid crystal molecules to be held such that they are aligned in a vertical direction without a PI layer, and improved alignment stability and low-temperature storage stability can be achieved.

The present invention provides a compound represented by formula (i), a liquid crystal composition using the compound, and a liquid crystal display device using the liquid crystal composition. The compound represented by formula (i) has a partial structure K.sup.i1 represented by any of general formulas (K-1) to (K-17) and further has ring B having at least two P-Sp- groups. Therefore, when used for a liquid crystal composition, the compound adsorbs to substrates sandwiching the liquid crystal composition (liquid crystal layer) and allows liquid crystal molecules to be held such that they are aligned in a vertical direction without a PI layer, and improved alignment stability and low-temperature storage stability can be achieved.

The application relates to a compound of Formula (I′) or (I):

##STR00001##

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.